Nab-paclitaxel + durvalumab as second- or third-line treatment of advanced NSCLC: results from ABOUND.2l+ by Govindan, R, Dols, MC, Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Vidal, O, Stewart, D, Ardizoni, A, Weaver, J, Wolfsteiner, M, Reck, M, Talbot, D, Morgensztern, D, Ong, TJ

ABOUND.2L+: nab-paclitaxel (nab-P) +/- CC-486 or durvalumab in previously treated patients with advanced non-small cell lung cancer (NSCLC) by Morgensztern, D, Ong, TJ, Dols, MC, Aix, SP, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, JR, Vidal, OJ, Stewart, DJ, Fasola, G, Ardizoni, A, Weaver, J, Wolfsteiner, M, Talbot, D, Govindan, R

Quality of life with second or third line nab-paclitaxel-based regimens in advanced non-small-cell lung cancer by Ponce Aix, S, Talbot, D, Ramaswamy, G, Cobo, M, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Jin Ong, T, Morgensztern, D

Quality of life in patients with advanced NSCLC treated in second- or third-line with nab-paclitaxel + durvalumab: abound.2l+ by Talbot, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Morgensztern, D, Ong, TJ

Efficacy and safety of second- or third-line nab-paclitaxel + durvalumab in patients with advanced NSCLC (ABOUND.2L+) by Morgensztern, D, Govindan, R, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, C, Bennouna, J, Fischer, J, Juan-Vidal, O, Stewart, D, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Reck, M, Talbot, D, Ong, TJ

ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer... by Morgensztern, D, Cobo, M, Ponce Aix, S, Postmus, PE, Lewanski, CR, Bennouna, J, Fischer, JR, Juan-Vidal, O, Stewart, DJ, Fasola, G, Ardizzoni, A, Bhore, R, Wolfsteiner, M, Talbot, DC, Jin Ong, T, Govindan, R, On Behalf Of The Abound L Investigators